Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free BDMD Stock Alerts

Baird Medical Investment (BDMD) Competitors

Baird Medical Investment logo
$1.28 +0.02 (+1.59%)
Closing price 06/8/2026 04:00 PM Eastern
Extended Trading
$1.30 +0.02 (+1.56%)
As of 07:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BDMD vs. PDEX, LUCD, EMBC, RXST, and STEX

Should you buy Baird Medical Investment stock or one of its competitors? MarketBeat compares Baird Medical Investment with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Baird Medical Investment include Pro-Dex (PDEX), Lucid Diagnostics (LUCD), Embecta (EMBC), RxSight (RXST), and Biosig Technologies (STEX). These companies are all part of the "medical equipment" industry.

How does Baird Medical Investment compare to Pro-Dex?

Baird Medical Investment (NASDAQ:BDMD) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Pro-Dex had 2 more articles in the media than Baird Medical Investment. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Baird Medical Investment. Pro-Dex's average media sentiment score of 0.68 beat Baird Medical Investment's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company Overall Sentiment
Baird Medical Investment Neutral
Pro-Dex Positive

Pro-Dex has a net margin of 16.08% compared to Baird Medical Investment's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Baird Medical Investment's return on equity.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
Pro-Dex 16.08%22.78%14.30%

Pro-Dex has higher revenue and earnings than Baird Medical Investment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.33N/AN/AN/A
Pro-Dex$66.59M3.11$8.98M$3.6217.96

Baird Medical Investment has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Pro-Dex has a consensus price target of $70.00, suggesting a potential upside of 7.69%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts clearly believe Pro-Dex is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pro-Dex
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Pro-Dex beats Baird Medical Investment on 11 of the 13 factors compared between the two stocks.

How does Baird Medical Investment compare to Lucid Diagnostics?

Baird Medical Investment (NASDAQ:BDMD) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Baird Medical Investment has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
Lucid Diagnostics -876.72%N/A -116.26%

Baird Medical Investment has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Baird Medical Investment has higher revenue and earnings than Lucid Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.33N/AN/AN/A
Lucid Diagnostics$5.13M37.90-$58.01M-$0.47N/A

Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 337.06%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lucid Diagnostics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Lucid Diagnostics had 2 more articles in the media than Baird Medical Investment. MarketBeat recorded 2 mentions for Lucid Diagnostics and 0 mentions for Baird Medical Investment. Lucid Diagnostics' average media sentiment score of 0.59 beat Baird Medical Investment's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Baird Medical Investment Neutral
Lucid Diagnostics Positive

Summary

Lucid Diagnostics beats Baird Medical Investment on 8 of the 12 factors compared between the two stocks.

How does Baird Medical Investment compare to Embecta?

Embecta (NASDAQ:EMBC) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, Embecta's average media sentiment score of 0.00 equaled Baird Medical Investment'saverage media sentiment score.

Company Overall Sentiment
Embecta Neutral
Baird Medical Investment Neutral

Embecta currently has a consensus target price of $11.00, indicating a potential upside of 229.34%. Given Embecta's stronger consensus rating and higher probable upside, equities research analysts clearly believe Embecta is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Embecta
3 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.40
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Embecta has a net margin of 10.73% compared to Baird Medical Investment's net margin of 0.00%. Baird Medical Investment's return on equity of 0.00% beat Embecta's return on equity.

Company Net Margins Return on Equity Return on Assets
Embecta10.73% -23.96% 14.12%
Baird Medical Investment N/A N/A N/A

93.8% of Embecta shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Embecta has higher revenue and earnings than Baird Medical Investment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Embecta$1.04B0.19$95.40M$1.901.76
Baird Medical Investment$22.54M2.33N/AN/AN/A

Embecta has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.22, indicating that its share price is 222% less volatile than the broader market.

Summary

Embecta beats Baird Medical Investment on 7 of the 10 factors compared between the two stocks.

How does Baird Medical Investment compare to RxSight?

Baird Medical Investment (NASDAQ:BDMD) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Baird Medical Investment's average media sentiment score of 0.00 equaled RxSight'saverage media sentiment score.

Company Overall Sentiment
Baird Medical Investment Neutral
RxSight Neutral

Baird Medical Investment has higher earnings, but lower revenue than RxSight.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.33N/AN/AN/A
RxSight$127.48M1.61-$38.94M-$1.13N/A

Baird Medical Investment has a net margin of 0.00% compared to RxSight's net margin of -36.58%. Baird Medical Investment's return on equity of 0.00% beat RxSight's return on equity.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
RxSight -36.58%-17.01%-15.12%

Baird Medical Investment has a beta of -1.22, meaning that its share price is 222% less volatile than the broader market. Comparatively, RxSight has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Comparatively, 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

RxSight has a consensus price target of $9.44, indicating a potential upside of 90.80%. Given RxSight's stronger consensus rating and higher possible upside, analysts plainly believe RxSight is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
RxSight
3 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.93

Summary

RxSight beats Baird Medical Investment on 6 of the 11 factors compared between the two stocks.

How does Baird Medical Investment compare to Biosig Technologies?

Baird Medical Investment (NASDAQ:BDMD) and Biosig Technologies (NASDAQ:STEX) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Biosig Technologies had 2 more articles in the media than Baird Medical Investment. MarketBeat recorded 2 mentions for Biosig Technologies and 0 mentions for Baird Medical Investment. Biosig Technologies' average media sentiment score of 0.29 beat Baird Medical Investment's score of 0.00 indicating that Biosig Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Baird Medical Investment Neutral
Biosig Technologies Neutral

Baird Medical Investment has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market. Comparatively, Biosig Technologies has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by company insiders. Comparatively, 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biosig Technologies has a consensus target price of $8.00, suggesting a potential upside of 711.85%. Given Biosig Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Baird Medical Investment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baird Medical Investment
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biosig Technologies
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Baird Medical Investment has higher revenue and earnings than Biosig Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baird Medical Investment$22.54M2.33N/AN/AN/A
Biosig Technologies$40K4,478.64-$462.77M-$9.71N/A

Baird Medical Investment's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Baird Medical InvestmentN/A N/A N/A
Biosig Technologies N/A -717.92%-336.75%

Summary

Biosig Technologies beats Baird Medical Investment on 7 of the 12 factors compared between the two stocks.

Get Baird Medical Investment News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDMD vs. The Competition

Export
MetricBaird Medical InvestmentMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$51.63M$7.18B$6.48B$11.98B
Dividend YieldN/A1.19%2.67%5.58%
P/E RatioN/A46.4123.6823.74
Price / Sales2.3384.17514.60115.22
Price / CashN/A25.1926.9937.25
Price / BookN/A6.8910.346.78
Net IncomeN/A$159.22M$3.57B$337.51M
7 Day Performance-4.48%-2.53%0.24%-2.34%
1 Month Performance-26.86%2.25%3.22%1.88%
1 Year Performance-72.71%-3.61%22.20%25.55%

Baird Medical Investment Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDMD
Baird Medical Investment
0.9012 of 5 stars		$1.28
+1.6%		N/A-71.5%$51.63M$22.54MN/AN/A
PDEX
Pro-Dex
2.6268 of 5 stars		$66.40
-0.5%		$70.00
+5.4%		+51.5%$211.82M$66.59M18.34140
LUCD
Lucid Diagnostics
3.8495 of 5 stars		$1.03
flat		$4.13
+300.5%		-25.7%$209.16M$5.13MN/A70
EMBC
Embecta
3.6438 of 5 stars		$3.39
-2.9%		$11.00
+224.5%		-65.9%$201.12M$1.04B1.781,850
RXST
RxSight
3.0466 of 5 stars		$4.75
-3.8%		$9.44
+98.8%		-67.1%$196.64M$127.48MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BDMD) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel